Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection

Belatacept is a biologic that targets CD80/86 and prevents its interaction with CD28 and its alternative ligand, cytotoxic T lymphocyte antigen 4 (CTLA-4). Clinical experience in kidney transplantation has revealed a high incidence of rejection with belatacept, especially with intensive regimens, su...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Am Soc Nephrol
Päätekijät: Ville, Simon, Poirier, Nicolas, Branchereau, Julien, Charpy, Vianney, Pengam, Sabrina, Nerriere-Daguin, Véronique, Le Bas-Bernardet, Stéphanie, Coulon, Flora, Mary, Caroline, Chenouard, Alexis, Hervouet, Jeremy, Minault, David, Nedellec, Steven, Renaudin, Karine, Vanhove, Bernard, Blancho, Gilles
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Nephrology 2016
Aiheet:
Basic Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118475/
https://ncbi.nlm.nih.gov/pubmed/27160407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015070774
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia